Skip to content
  • Facebook
  • Twitter
This translation is automatically provided by Google; please refer to the original English version for appropriate wording.
Take on Typhoid

Take on Typhoid

  • Home
  • Why Typhoid?
    • Typhoid & Related Salmonelloses
    • Global Research
    • Links & Resources
  • The Issues
    • Vaccines
    • WASH
    • Drug-Resistant Typhoid
    • Treatment
    • Diagnostics
    • Related Issues
  • Resources & Tools
    • Talk About Typhoid
    • Global Policy
    • Country Tools
    • Infographics
    • Fact Sheets
    • TCV Cost-effectiveness
    • Share on Social
  • Blog & News
    • Blog
    • News
    • Publications
    • Newsletter
  • International Conference
    • Past Conferences
  • About Us
    • About the Coalition against Typhoid
    • About the Typhoid Vaccine Acceleration Consortium

TCV is highly immunogenic in Malawian children

Posted on September 15, 2021 by Laura Kallen

New results from an immune response study in Malawi found that TCV may offer longer-lasting protection of up to three years for children as young as 9 months old!

learn more

Post navigation

Now we know: typhoid conjugate vaccines are highly effective in African children
Take on Typhoid Newsletter September 2021

Related Posts

  • Country Tools

  • Reaching every child in Pakistan

  • Why TCV now? Why not? Asia Regional Meeting held in Dhaka, Bangladesh

Newsletter Signup

Recent Posts

  • Illegal mining in Ghana: The negative impact on WASH, typhoid, and other infectious diseases

  • A glance at the past and looking forward to 2023

  • Prioritizing TCV introduction in Africa: Time for decision-makers to act with urgency

  • Typhoid takes a spotlight during the 2022 VASE Conference

  • Test-negative design proves to be suitable for typhoid vaccine effectiveness evaluations

cat
685 West Baltimore Street, Room 480
Baltimore, MD 21201-1509
Coalition against Typhoid
2175 K Street, NW, Suite 400
Washington, DC 20037
© 2018. Coalition Against Typhoid. All Rights Reserved.
  • Contact Us
  • Privacy Policy
  • Facebook
  • Twitter
Top